Table 1.
Baseline patients and persistent febrile neutropenia episodes characteristics
| Baseline characteristics | No. of subjects (%)b |
P | |
|---|---|---|---|
| DDAT approachc | Standard approachd | ||
| Patients | |||
| PFNa episodes/no. of patients | 85/72 | 1,095/1,095 | |
| Sex, male | 41 (56.9) | 610 (55.7) | NSe |
| Median age (range) | 47 (15–75) | 50 (16–83) | NS |
| Underlying disease | |||
| Acute myeloblastic leukemia | 25 (34.7) | 703 (64.2) | <0.001 |
| Acute lymphoblastic leukemia | 4 (4.7) | 107 (9.8) | NS |
| Lymphoma | 18 (25) | 120 (10.9) | <0.001 |
| Others | 25 (34.7) | 165 (15.1) | <0.001 |
| High-risk patients | 25 (34.7) | 268 (24.4) | NS |
| Allogeneic HSCT recipients | 15 (20.08) | 75 (6.8) | <0.001 |
| Relapse of acute leukemia | 10 (13.9) | 193 (17.6) | NS |
| Neutrophil count <100/mm3, no. (%) | 84 (98.8) | 806 (73.6) | <0.001 |
| First-line antifungal agents, no. (%) | 52 (61.2) | 1,095 (100) | <0.001 |
| Liposomal amphotericin | 4 (2.4) | 539 (49.2) | |
| Caspofungin | 24 (28.2) | 556 (50.8) | |
| Voriconazole | 23 (27.1) | ||
| Fluconazole | 2 (2.4) | ||
| No antifungal therapy | 33 (38.8) | ||
| Patients that developed IFI | 12* | 107† | NS |
PFN, persistent febrile neutropenia.
Values are presented as the “number of subjects (%)”except as noted otherwise in column 1. *, Eleven were baseline IFI and one was a breakthrough IFI; †, 54 were baseline IFI and the rest were breakthrough IFI.
For the DDAT approach, the results of EAT were extrapolated from the study cohort reported by Aguilar-Guisado M et al. (14) in which the hematological patients with PFN were managed according to SAEI guidelines (12).
For the standard approach, the results were extrapolated from the randomized trial reported by Walsh et al. (7). In this study, hematological patients with PFN were managed according to IDSA recommendations (4) indicating EAT.
NS, not significant.